The Winniedel Oncology Blog
At Winniedel Oncology, we specialize in expediting study start-up (SSU) for early-phase (FIH-2b) oncology clinical trials. Discover how our expertise can streamline your clinical development journey and make a meaningful impact in the fight against cancer.
Why KOLs Need a Seat at the Table Before the Protocol Is Locked, Not After
Protocol amendments cost sponsors a median of $535,000 in Phase III, and 45% are avoidable. In early-phase oncology, restrictive eligibility criteria add nine months to accrual without a significant difference in safety. Learn why bringing KOLs and PIs into protocol design before submission speeds study start-up and protects your oncology trial.